CytoSorbents Corporation is a critical care focused therapeutic device company using blood purification to treat life-threatening illnesses. The Company's purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Each polymer bead contains millions of pores and channels that can be modified to remove substances as small as drugs, to substances as large as antibodies.
TypePublic
HQSouth Brunswick Township, US
Founded2002
Size (employees)65 (est)
Websitecytosorbents.com
Cytosorbents was founded in 2002 and is headquartered in South Brunswick Township, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Cytosorbents

Phillip Chan

Phillip Chan

Chief Executive Officer and President
Kathleen Bloch

Kathleen Bloch

CFO
Vincent Capponi

Vincent Capponi

COO
Robert Bartlett

Robert Bartlett

Chief Medical Officer
Show more

Cytosorbents Office Locations

Cytosorbents has an office in South Brunswick Township
South Brunswick Township, US (HQ)
k 7 Deerpark Dr
Show all (1)
Report incorrect company information

Cytosorbents Financials and Metrics

Cytosorbents Revenue

Embed Graph
Cytosorbents's revenue was reported to be $15.15 m in FY, 2017 which is a 59% increase from the previous period.
USD

Revenue (FY, 2017)

15.2m

Revenue growth (FY, 2016 - FY, 2017), %

59%

Gross profit (FY, 2017)

9.6m

Gross profit margin (FY, 2017), %

63.6%

Net income (FY, 2017)

(8.5m)

EBIT (FY, 2017)

(9.8m)

Market capitalization (15-Oct-2018)

338.2m

Closing stock price (15-Oct-2018)

10.8

Cash (31-Dec-2017)

17.3m

EV

330.9m
Cytosorbents's current market capitalization is $338.2 m.
USDFY, 2015FY, 2016FY, 2017

Revenue

4.8m9.5m15.2m

Revenue growth, %

99%59%

Cost of goods sold

2.2m4.0m5.5m

Gross profit

2.6m5.6m9.6m
USDFY, 2015FY, 2016FY, 2017

Cash

5.3m5.2m17.3m

Accounts Receivable

648.9k1.4m2.2m

Prepaid Expenses

511.9k315.8k416.0k

Inventories

1.2m834.0k795.7k
USDFY, 2015FY, 2016FY, 2017

Net Income

(8.1m)(11.8m)(8.5m)

Depreciation and Amortization

113.0k161.6k218.3k

Inventories

(671.3k)340.4k57.3k

Accounts Payable

(83.2k)2.1m523.4k
USDY, 2017

EV/EBIT

-33.6 x

EV/CFO

-51.2 x

Revenue/Employee

233.1k

Debt/Equity

1 x

Debt/Assets

0.4 x

Financial Leverage

2.3 x

P/E Ratio

(33.6)
Show all financial metrics
Report incorrect company information

Cytosorbents Online and Social Media Presence

Embed Graph
Report incorrect company information

Cytosorbents News and Updates

Report incorrect company information

Cytosorbents Blogs

CytoSorbents to Present at the Cantor Fitzgerald Global Healthcare Conference

MONMOUTH JUNCTION, N.J., Oct. 3, 2018 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its Chief …

CytoSorbents to Present at the B. Riley FBR Healthcare Conference and the H.C. Wainwright 20th Annual Global Investment Conference

MONMOUTH JUNCTION, N.J., Aug. 28, 2018 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its Chief…

CytoSorbents Awarded up to $3M in SBIR Phase IIB Bridge Funding by NIH/NHLBI to Accelerate U.S. Approval and Commercialization of the HemoDefend™ Blood Transfusion Filter

MONMOUTH JUNCTION, N.J., Aug. 21, 2018 /PRNewswire/ — CytoSorbents Corporation (Nasdaq: CTSO) a critical care immunotherapy leader specializing in blood purification, announced today that the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), ha…

CytoSorbents to Report Q2 2018 Operating and Financial Results

MONMOUTH JUNCTION, N.J., July 26, 2018 /PRNewswire/ — CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q2 2018 fi…

Aferetica and CytoSorbents Debut the PerLife™ System for Organ Preservation and Rehabilitation at the 27th International Congress of the Transplantation Society

PerLife™ Is the First System Integrating a Sorbent Purification Technology to Perfuse, Cleanse, Recondition, and Preserve Harvested Solid Organs for Transplantation MIRANDOLA, Italy and MONMOUTH JUNCTION, N.J., July 9, 2018 /PRNewswire/ — Aferetica srl, an innovative start-up specializing in purific…

CytoSorbents Officially Opens New U.S. CytoSorb Manufacturing Facility

New facility quadruples production capacity and is expected to accelerate margin expansion and drive operating profitability MONMOUTH JUNCTION, N.J., June 12, 2018 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification tech…
Show more

Cytosorbents Company Life and Culture

Report incorrect company information